Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
17/07/2025
Xiaopeng Motors: Xiaopeng Charging added 23 new self-operated stations in the 26th week of 2025, including 3 S5 super fast charging stations, 17 S4 super fast charging stations, and 3 destination stations.
Latest
3 m ago
Shandong Gold Geological Mineral Exploration Company's registered capital has increased to 600 million yuan.
3 m ago
Ideal car: The Ideal i8 is now available for pre-order. The estimated selling price for the Ideal i8 is between 350,000 to 400,000 RMB, the official price will be announced at the press conference on July 29th. Customers who pre-order from July 17th to July 29th will have priority delivery rights after confirming the purchase.
3 m ago
Kang Ning Jerry Pharmaceuticals rose by 4.1%, with several senior executives purchasing a total of 900,000 shares.
4 m ago
Printed circuit board stocks rise, Bonc Intelligent and Mankun Technology increase by more than 10%.
5 m ago
Hong Kong Stock Market Abnormal Movement | BeiGene (06160.HK) Surges Over 6% Again. Application for approval of market release of DLL3/CD3 bispecific antibody tislelizumab accepted.
See all latest